Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other Working Capital Changes (2019 - 2025)

Historic Other Working Capital Changes for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $122000.0.

  • Eton Pharmaceuticals' Other Working Capital Changes fell 2327.04% to $122000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 51363.64%. This contributed to the annual value of $3.3 million for FY2024, which is 366276.6% up from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Other Working Capital Changes is $122000.0, which was down 2327.04% from $2.3 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $3.5 million during Q4 2024, with a 5-year trough of -$3.0 million in Q1 2025.
  • Its 5-year average for Other Working Capital Changes is $99526.3, with a median of -$79000.0 in 2024.
  • In the last 5 years, Eton Pharmaceuticals' Other Working Capital Changes surged by 140000.0% in 2021 and then crashed by 366329.11% in 2025.
  • Eton Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $743000.0 in 2021, then plummeted by 61.1% to $289000.0 in 2022, then soared by 126.64% to $655000.0 in 2023, then soared by 437.4% to $3.5 million in 2024, then plummeted by 96.53% to $122000.0 in 2025.
  • Its last three reported values are $122000.0 in Q3 2025, $2.3 million for Q2 2025, and -$3.0 million during Q1 2025.